AbbVie and Genmab have reported data from the Phase I/II EPCORE NHL-1 clinical trial of T-cell engaging bispecific antibody epcoritamab (DuoBody CD3xCD20) in adults with relapsed/refractory (r/r) follicular lymphoma (FL).

AbbVie and Genmab have reported data on their recently approved bi-specific antibody in a second cancer indication, positioning them to talk to regulators about filings to challenge Roche.

Big Pharma’s competition in the anti-CD20 bispecific space is taking shape, with the FDA on Friday approving what analysts view as a best-in-class blood cancer drug.

AbbVie and Genmab's epcoritamab has won accelerated approval to treat diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. The drug now bears the commercial moniker Epkinly.

AbbVie and Genmab have glided into Roche’s slipstream in the race to bring a CD3xCD20 bispecific to market, securing FDA priority review and a May decision date—and triggering an $80 million milestone payment in the process. 

Danish biotechnology company Genmab A/S and Chicago biotech behemoth AbbVie announced primary results from the Phase II expansion cohort of their EPCORE NHL-1 clinical trial. The data revealed that the investigational bispecific antibody, epcoritamab, induced a deep and durable response in patients with large B-cell lymphoma (LBCL).

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead drug in the partnership – epcoritamab for large B-cell lymphoma (LBCL).

AbbVie is set to pay Genmab $750 million upfront for a stake in a pipeline of anti-cancer bispecifics led by epcoritamab. The deal, which features up to $3.2 billion in milestones, positions AbbVie to race Regeneron to market with a bispecific antibody that could compete with CAR-T therapies.